Chiba Toshimi, Kudara Norihiko, Abiko Yukito, Endo Masaki, Suzuki Kazuyuki, Sugai Tamotsu, Ishijima Ken, Fukuda Koji, Yamazaki Kazuharu, Sato Hiroaki
Department of Internal Medicine, Iwate Medical University, Iwate, Japan.
Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1580-2. doi: 10.5754/hge09607. Epub 2011 Jul 15.
BACKGROUND/AIMS: The effect of proton pump inhibitors (PPIs) on the health-related quality of life (HRQoL) of patients with laryngopharyngeal reflux disease (LPRD) is not well known. Our aim was to assess the HRQoL before and after administration of a PPI in patients with LPRD.
A total of 27 LPRD patients (14 women, 13 men; mean age 54 years) were enrolled. We determined the HRQoL using three different inquiry systems: 1) Frequency Scale for the Symptoms of GERD (FSSG); 2) the 36 item short form of the Medical Outcome Study Questionnaire (SF-36); and 3) the Gastrointestinal Symptom Rating Scale (GSRS). The HRQoL was determined at baseline and after eight weeks of treatment with lansoprazole at a dose of 30mg once daily or rabeprazole at a dose of 10mg once daily.
After administration of the PPI, the FSSG, the SF-36 general health scale and mental health scale, GSRS reflux syndrome score, abdominal pain syndrome score and the indigestion syndrome score were significantly improved compared to baseline pretreatment scores (p<0.05).
PPI therapy would be useful for the treatment of LPRD.
背景/目的：质子泵抑制剂（PPIs）对喉咽反流病（LPRD）患者健康相关生活质量（HRQoL）的影响尚不清楚。我们的目的是评估LPRD患者服用PPI前后的HRQoL。
共纳入27例LPRD患者（14例女性，13例男性；平均年龄54岁）。我们使用三种不同的询问系统来确定HRQoL：1）胃食管反流病症状频率量表（FSSG）；2）医学结局研究问卷简表36项（SF-36）；3）胃肠道症状评定量表（GSRS）。在基线时以及用30mg兰索拉唑每日一次或10mg雷贝拉唑每日一次治疗八周后确定HRQoL。
服用PPI后，与基线治疗前评分相比，FSSG、SF-36总体健康量表和心理健康量表、GSRS反流综合征评分、腹痛综合征评分和消化不良综合征评分均有显著改善（p<0.05）。
PPI治疗对LPRD的治疗有效。
